Frankie Fattorini, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/frankiefattorini/ Hard data and deep insights on clinical trials strategy & operations Thu, 07 Nov 2024 17:21:03 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-32x32.png Frankie Fattorini, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/frankiefattorini/ 32 32 Minister for Science champions partnerships with private clinical sector in UK https://www.clinicaltrialsarena.com/news/minister-for-science-champions-partnerships-with-private-clinical-sector-in-uk/ Thu, 07 Nov 2024 17:17:02 +0000 https://www.clinicaltrialsarena.com/uncategorized/minister-for-science-champions-partnerships-with-private-clinical-sector-in-uk/ Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

The post Minister for Science champions partnerships with private clinical sector in UK appeared first on Clinical Trials Arena.

]]> The post Minister for Science champions partnerships with private clinical sector in UK appeared first on Clinical Trials Arena.

]]> Lord O’Shaughnessy expresses optimism for clinical trials in the UK https://www.clinicaltrialsarena.com/news/lord-oshaughnessy-expresses-optimism-for-clinical-trials-in-the-uk/ Wed, 06 Nov 2024 20:12:40 +0000 https://www.clinicaltrialsarena.com/uncategorized/lord-oshaughnessy-expresses-optimism-for-clinical-trials-in-the-uk/ The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

The post Lord O’Shaughnessy expresses optimism for clinical trials in the UK appeared first on Clinical Trials Arena.

]]> The post Lord O’Shaughnessy expresses optimism for clinical trials in the UK appeared first on Clinical Trials Arena.

]]> Arrivo targets major depressive disorder in females after early efficacy data https://www.clinicaltrialsarena.com/news/arrivo-targets-major-depressive-disorder-in-females-after-early-efficacy-data/ Tue, 29 Oct 2024 17:05:02 +0000 https://www.clinicaltrialsarena.com/uncategorized/arrivo-targets-major-depressive-disorder-in-females-after-early-efficacy-data/ The SIRT6 activator’s sex-specific effects shed light on the different genetic profiles of depression between men and women.

The post Arrivo targets major depressive disorder in females after early efficacy data appeared first on Clinical Trials Arena.

]]> The post Arrivo targets major depressive disorder in females after early efficacy data appeared first on Clinical Trials Arena.

]]> A slow start for self-amplifying mRNA vaccines https://www.clinicaltrialsarena.com/uncategorized/a-slow-start-for-self-amplifying-mrna-vaccines/ Wed, 23 Oct 2024 07:00:00 +0000 https://www.clinicaltrialsarena.com/uncategorized/a-slow-start-for-self-amplifying-mrna-vaccines/

The post A slow start for self-amplifying mRNA vaccines appeared first on Clinical Trials Arena.

]]>

The post A slow start for self-amplifying mRNA vaccines appeared first on Clinical Trials Arena.

]]> Amgen and MediLink to collaborate on SCLC combination therapy https://www.clinicaltrialsarena.com/news/amgen-and-medilink-to-collaborate-on-sclc-combination-therapy/ Tue, 08 Oct 2024 16:22:22 +0000 https://www.clinicaltrialsarena.com/uncategorized/amgen-and-medilink-to-collaborate-on-sclc-combination-therapy/ The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung cancer.

The post Amgen and MediLink to collaborate on SCLC combination therapy appeared first on Clinical Trials Arena.

]]> The post Amgen and MediLink to collaborate on SCLC combination therapy appeared first on Clinical Trials Arena.

]]> BMS and Prime ink potential $3.5bn deal to develop T cell therapies https://www.clinicaltrialsarena.com/news/bms-and-prime-ink-potential-3-5bn-deal-to-develop-t-cell-therapies/ Tue, 01 Oct 2024 13:25:13 +0000 https://www.clinicaltrialsarena.com/uncategorized/bms-and-prime-ink-potential-3-5bn-deal-to-develop-t-cell-therapies/ As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine.

The post BMS and Prime ink potential $3.5bn deal to develop T cell therapies appeared first on Clinical Trials Arena.

]]> The post BMS and Prime ink potential $3.5bn deal to develop T cell therapies appeared first on Clinical Trials Arena.

]]> AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients https://www.clinicaltrialsarena.com/news/astrazeneca-daiichis-adc-shows-better-survival-for-nonsquamous-nsclc-patients/ Tue, 10 Sep 2024 16:52:12 +0000 https://www.clinicaltrialsarena.com/uncategorized/astrazeneca-daiichis-adc-shows-better-survival-for-nonsquamous-nsclc-patients/ Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall survival than chemotherapy.

The post AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients appeared first on Clinical Trials Arena.

]]> The post AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients appeared first on Clinical Trials Arena.

]]>